Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Consulting agrmnt
Appointed CFO
Quarterly results
Appointed director
CC transcript
Inv. presentation
Sucampo Pharmaceuticals, Inc. (SCMP) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/23/2018 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
02/16/2018 EFFECT Form EFFECT - Notice of Effectiveness:
02/16/2018 EFFECT Form EFFECT - Notice of Effectiveness:
02/16/2018 EFFECT Form EFFECT - Notice of Effectiveness:
02/16/2018 EFFECT Form EFFECT - Notice of Effectiveness:
02/15/2018 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/15/2018 SC 13D/A Ueno Ryuji reports a 0% stake in Sucampo Pharmaceuticals, Inc.
02/13/2018 SC 13G/A ING GROEP NV reports a 0% stake in Sucampo Pharmaceuticals, Inc.
02/13/2018 SC 13G LSV ASSET MANAGEMENT reports a 5.3% stake in SUCAMPO PHARMACEUTICALS, INC.
02/13/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/13/2018 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/13/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/13/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/13/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/13/2018 POS AM Form POS AM - Post-Effective amendments for registration statement:
02/13/2018 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation of Sucampo Pharmaceuticals, Inc",
"Amended and Restated Bylaws of Sucampo Pharmaceuticals, Inc",
"Supplemental Indenture, between Sucampo Pharmaceuticals, Inc. and U.S. Bank National Association, as Trustee"
02/13/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
02/13/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
02/13/2018 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
02/12/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
02/12/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
02/09/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
02/09/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
02/08/2018 SC 13G BlackRock Inc. reports a 8.8% stake in SUCAMPO PHARMACEUTICALS INC
02/08/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
02/07/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
02/05/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
02/05/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
01/30/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
01/30/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
01/25/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
01/25/2018 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
01/18/2018 GN Consolidated Research: 2018 Summary Expectations for Sucampo Pharmaceuticals, Hersha Hospitality Trust, Archrock, SJW, Franklin Financial Network, and Digi International — Fundamental Analysis, Key Performance Indications
01/17/2018 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy